Thyroid Eye Disease (TED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Thyroid eye disease (TED) is a rare, debilitating autoimmune disease known as Graves' orbitopathy or thyroid-associated ophthalmopathy. After 1 to 3 years, the disease progresses from an active progressive period marked by inflammation to a stable and fibrotic period. It affects approximately 40% of Graves' disease patients. In Graves' disease, autoantibodies (thyroid-stimulating immunoglobulin) targeting the thyrotropin receptor cause hyperthyroidism. The insulin-like growth factor I receptor (IGF-IR), which is overexpressed by orbital fibroblasts and B and T cells, plays a critical role in Graves' illness and thyroid eye disease. Thyrotropin receptors and IGF-IRs form physical and functional complexes that cause hyaluronan accumulation and cytokine production, resulting in inflammation, edema, and enlargement of extraocular muscle and adipose tissue.

·       The incidence of Thyroid eye disease in the USA is 15 to 20 cases per 100,000 population in the USA.

 

Thelansis’s “Thyroid Eye Disease (TED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thyroid Eye Disease (TED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Thyroid Eye Disease (TED) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Thyroid Eye Disease (TED) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Thyroid Eye Disease (TED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Thyroid Eye Disease (TED), Thyroid Eye Disease (TED) market outlook, Thyroid Eye Disease (TED) competitive landscape, Thyroid Eye Disease (TED) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034